CardiacAssist gets US OK for TandemHeart PTVA (percutaneous transseptal ventricular assist) technology:
This article was originally published in Clinica
CardiacAssist can now market in the US its TandemHeart percutaneous transseptal ventricular assist (PTVA) system for short-term circulatory support, after gaining FDA 510(k) clearance for the product's final component: the transseptal cannula. The TandemHeart PTVA device was previously CE-marked for sale in Europe in 2000. It can be used to support critically ill patients with heart failure and cardiogenic shock. The system is currently being compared with conventional intra aortic balloon pump therapy in a cardiogenic shock trial in the US, says the Pittsburgh, Pennsylvania firm.
You may also be interested in...
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.
The French major and Regeneron have racked up another indication for Dupixent with the blockbuster getting approval in Europe to treat children with severe eczema.
Russia says it will make the first deliveries of its $10-per-dose Sputnik V vaccine in January, while international regulators say vaccine trials should continue for as long as possible to generate longer-term evidence on their benefits and risks. A UK research body has stressed that drugs repurposed for COVID-19 also need to undergo thorough safety and efficacy testing as reports suggest the UK regulator could approve a vaccine within days.